

Journal of Visualized Experiments

Single-cell factor localization on chromatin using ultra-low input Cleavage Under Targets and Release Using Nuclease --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE63536R2
Full Title:	Single-cell factor localization on chromatin using ultra-low input Cleavage Under Targets and Release Using Nuclease
Corresponding Author:	Sarah J Hainer, Ph.D University of Pittsburgh Pittsburgh, PA UNITED STATES
Corresponding Author's Institution:	University of Pittsburgh
Corresponding Author E-Mail:	sarah.hainer@pitt.edu
Order of Authors:	Santana Lardo Sarah J Hainer, Ph.D
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Biology
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (\$1400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Pittsburgh, PA USA
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the Video Release
Please provide any comments to the journal here.	

TITLE:

Single-Cell Factor Localization on Chromatin Using Ultra-Low Input Cleavage Under Targets and Release Using Nuclease

AUTHORS AND AFFILIATIONS:

Santana M. Lardo¹, Sarah J. Hainer^{1*}

¹Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15213

*Corresponding Author:

Sarah J. Hainer (sarah.hainer@pitt.edu)

Email addresses of co-authors:

Santana M. Lardo (sml111@pitt.edu)

Sarah J. Hainer (sarah.hainer@pitt.edu)

SUMMARY:

CUT&RUN and its variants can be used to determine protein occupancy on chromatin. This protocol describes how to determine protein localization on chromatin using single-cell uliCUT&RUN.

ABSTRACT:

Determining the binding locations of a protein on chromatin is essential for understanding its function and potential regulatory targets. Chromatin Immunoprecipitation (ChIP) has been the gold standard for determining protein localization for over 30 years and is defined by the use of an antibody to pull out the protein of interest from sonicated or enzymatically digested chromatin. More recently, antibody tethering techniques have become popular for assessing protein localization on chromatin due to their increased sensitivity. Cleavage Under Targets & Release Under Nuclease (CUT&RUN) is the genome-wide derivative of Chromatin Immunocleavage (ChIC) and utilizes recombinant Protein A tethered to micrococcal nuclease (pA-MNase) to identify the IgG constant region of the antibody targeting a protein of interest, therefore enabling site-specific cleavage of the DNA flanking the protein of interest. CUT&RUN can be used to profile histone modifications, transcription factors, and other chromatin-binding proteins such as nucleosome remodeling factors. Importantly, CUT&RUN can be used to assess the localization of either euchromatic- or heterochromatic-associated proteins and histone modifications. For these reasons, CUT&RUN is a powerful method for determining the binding profiles of a wide range of proteins. Recently, CUT&RUN has been optimized for transcription factor profiling in low populations of cells and single cells and the optimized protocol has been termed ultra-low input CUT&RUN (uliCUT&RUN). Here, a detailed protocol is presented for single-cell factor profiling using uliCUT&RUN in a manual 96-well format.

INTRODUCTION:

Many nuclear proteins function by interacting with chromatin to promote or prevent DNA-templated activities. To determine the function of these chromatin-interacting proteins, it is

important to identify the genomic locations at which these proteins are bound. Since its development in 1985, Chromatin Immunoprecipitation (ChIP) has been the gold standard for identifying where a protein binds to chromatin^{1,2}. The traditional ChIP technique has the following basic workflow: cells are harvested and crosslinked (usually with formaldehyde), chromatin is sheared (usually with harsh sonication methods, necessitating crosslinking), the protein of interest is immunoprecipitated using an antibody that targets the protein (or tagged protein) followed by a secondary antibody (coupled to agarose or magnetic beads), crosslinking is reversed, protein and RNA are digested to purify DNA, and this ChIP enriched-DNA is used as the template for analysis (using radiolabeled probes^{1,2}, qPCR³, microarrays^{5,6}, or sequencing⁴). With the advent of microarrays and massively parallel deep sequencing, ChIP-chip^{5,6} and ChIP-seq⁴ have more recently been developed and allow for genome-wide identification of protein localization on chromatin. Crosslinking ChIP has been a powerful and reliable technique since its advent with major advances in resolution by ChIP-exo⁷ and ChIP-nexus⁸. In parallel to the development of ChIP-seq, native (non-crosslinking) protocols for ChIP (N-ChIP) have been established, which utilize nuclease digestion (often using a micrococcal nuclease or MNase) to fragment the chromatin, as opposed to sonication performed in traditional crosslinking ChIP techniques⁹. However, one major drawback to both crosslinking ChIP and N-ChIP technologies has been the requirement for high cell numbers due to low DNA yield following the experimental manipulation. Therefore, in more recent years, many efforts have been toward optimizing ChIP technologies for low cell input. These efforts have resulted in the development of many powerful ChIP-based technologies that vary in their applicability and input requirements¹⁰⁻¹⁸. However, single-cell ChIP-seq based technologies have been lacking, especially for non-histone proteins.

In 2004, an alternative technology was developed to determine protein occupancy on chromatin termed Chromatin Endogenous Cleavage (ChEC) and Chromatin Immunocleavage (ChIC)¹⁹. These single-locus techniques utilize a fusion of MNase to either the protein of interest (ChEC) or to protein A (ChIC) for direct cutting of DNA adjacent to the protein of interest. In more recent years, both ChEC and ChIC have been optimized for genome-wide protein profiling on chromatin (ChEC-seq and CUT&RUN, respectively)^{20,21}. While ChEC-seq is a powerful technique for determining factor localization, it requires developing MNase-fusion proteins for each target, whereas ChIC and its genome-wide variation, CUT&RUN, rely on an antibody directed toward the protein of interest (as with ChIP) and recombinant Protein A-MNase, where the Protein A can recognize the IgG constant region of the antibody. As an alternative, a fusion Protein A/Protein G-MNase (pA/G-MNase) has been developed that can recognize a broader range of antibody constant regions²². CUT&RUN has rapidly become a popular alternative to ChIP-seq for determining protein localization on chromatin genome-wide.

Ultra-low input CUT&RUN (uliCUT&RUN), a variation of CUT&RUN that enables the use of low and single-cell inputs, was described in 2019²³. Here, the methodology for a manual 96-well format single-cell application is described. It is important to note that since the development of uliCUT&RUN, two alternatives for histone profiling, CUT&Tag and iACT-seq have been developed, providing robust and highly parallel profiling of histone proteins^{24,25}. Furthermore, scCUT&Tag has been optimized for profiling multiple factors in a single cell (multiCUT&Tag) and for application to non-histone proteins²⁶. Together, CUT&RUN provides an attractive alternative to

low input CHIP-seq where uliCUT&RUN can be performed in any molecular biology lab that has access to a cell sorter and standard equipment.

PROTOCOL:

Ethics statement: All studies were approved by the Institutional Biosafety Office of Research Protections at the University of Pittsburgh.

1. Prepare magnetic beads

NOTE: Perform prior to cell sorting and hold on ice until use.

1.1. Pipette 30 μ L of ConA-conjugated paramagnetic microspheres bead slurry mix per reaction to a fresh 1.5 mL microfuge tube and add 850 μ L of Binding Buffer, pipetting gently to mix.

NOTE: ConA-conjugated paramagnetic microspheres are lectin-coated magnetic beads that permit lipid membrane binding.

1.2. Place the tube on a magnetic rack and allow the beads to magnetize for 1–2 min. Once the supernatant has cleared, remove, and discard the supernatant without disturbing the beads.

1.3. Remove the tube from the magnetic rack and wash the beads by resuspending in 1 mL of Binding Buffer.

1.4. Repeat steps 1.2 and 1.3.

1.5. Magnetize the beads for 2 min and remove the supernatant to discard.

1.6. Remove the tube from the magnetic rack and resuspend the beads in 30 μ L of Binding Buffer per reaction.

1.7. Hold the washed bead mix on ice until cells are sorted.

2. Harvest cells

NOTE: This step is written for adhered cells and optimized for murine E14 embryonic stem cells. Culturing and harvesting the cells depend on the cell type.

2.1. Remove the cells from the 37 °C incubator and examine them under a microscope to assure quality.

2.2. Aspirate the media from the cell plate and rinse with 5 mL of 1x PBS.

2.3. Aspirate PBS from the plate and harvest the cells (using traditional cell harvesting methods which will differ by cell type). Obtain single-cell suspension by gently pipetting up and down with a serological pipette against the culture dish, if necessary.

2.4. Transfer the cell suspension to a 15 mL conical tube and spin down at 200 x *g* for 5 min.

2.5. Aspirate off the media to discard and wash the cell pellet with 5 mL of PBS + 1% FBS.

2.6. Spin down the cells at 200 x *g* for 5 min, discard the supernatant, and resuspend the cell pellet in 5 mL of PBS + 1% FBS.

2.7. Count the cells and transfer 1 mL of 1×10^6 cells into a fresh 1.5 mL microfuge tube.

2.8. Add 5 μ L of 7-Amino-Actinomycin D (7-AAD), invert the well to mix, and then apply the sample to the cell sorter to sort live single cells into individual wells of a 96-well plate.

NOTE: 7-AAD dye is excluded from live cells, and therefore can be used in live-cell sorting.

3. Cell sorting and lysis

3.1. Prepare a cell sorter-compatible 96-well plate with 100 μ L of Nuclear Extraction (NE) Buffer in each well prior to cell sorting.

3.2. Sort the cells into 96-well plates following the manufacturer's instructions.

3.3. Quickly spin the plate (600 x *g* for 30 s) to assure cells are in the buffer within the wells.

NOTE: It is worth testing in a preliminary experiment whether the cells being used are reliably brought to the bottom of the wells.

3.4. Hold the samples on ice for 15 min.

3.5. Spin down the samples at 600 x *g* for 5 min at 4 °C and carefully pipette to remove the supernatant (leaving behind 5 μ L).

3.6. Resuspend each sample in 55 μ L of NE buffer and add 30 μ L of the prewashed ConA-conjugated paramagnetic microspheres (from step 1.7; in Binding Buffer) to each reaction.

3.7. Incubate at room temperature for 10 min.

4. Pre-block samples to prevent early digestion by MNase

4.1. Place the plate on a 96-well magnetic rack, allow the beads to bind for a minimum of 5 min, and then remove and discard the supernatant.

175
176 4.2. Add 100 μ L of Blocking Buffer to the nucleus-bound beads and mix with gentle pipetting.

177
178 4.3. Incubate for 5 min at room temperature.

179
180 **5. Addition of primary antibody**

181
182 5.1. Place the plate on a 96-well magnetic rack, allow the supernatant to clear for a minimum of
183 5 min, and then remove and discard the supernatant without disturbing the beads.

184
185 5.2. Remove the plate from the magnetic rack and resuspend the beads in 100 μ L of Wash Buffer
186 per reaction with gentle pipetting.

187
188 5.3. Place the plate back on the 96-well magnetic rack, allow the supernatant to clear, and then
189 remove and discard the supernatant.

190
191 5.4. Resuspend the beads in 25 μ L of Wash Buffer per reaction with gentle pipetting.

192
193 5.5. Make a primary antibody master mix: 25 μ L of Wash Buffer + 0.5 μ L of antibody per reaction.

194
195 5.6. While gently vortexing the nuclei-bound beads, add 25 μ L of the primary antibody master
196 mix to each sample being treated with an antibody targeting the protein of interest (typically
197 1:100 final dilution). Add 25 μ L of Wash Buffer with no antibody, if performing a control.

198
199 5.7. Incubate for 1 h at room temperature.

200
201 5.8. Place the samples on a 96-well magnetic rack, allow the supernatant to clear for a minimum
202 of 5 min, and then remove and discard the supernatant without disturbing the beads.

203
204 5.9. Remove the plate from the magnetic rack and wash the beads with 100 μ L of Wash Buffer,
205 resuspending by pipetting.

206
207 **6. Addition of pA-MNase or pA/G-MNase**

208
209 NOTE: Protein A has a high affinity for IgG molecules from certain species such as rabbits but is
210 not suitable for IgGs from other species such as mice or rats. Alternatively, Protein A/G-MNase
211 can be used. This hybrid binds rabbit, mouse, and rat IgGs, avoiding the need for secondary
212 antibodies when mouse or rat primary antibodies are used.

213
214 6.1. Place the plate back on a 96-well magnetic rack, allow the supernatant to clear for a
215 minimum of 5 min, and then remove and discard the supernatant without disturbing the beads.

216
217 6.2. Remove the plate from the magnetic rack and resuspend each sample in 25 μ L of Wash
218 Buffer.

6.3. Make a pA-MNase master mix (25 μ L of Wash Buffer + optimized amount of pA-MNase per reaction).

6.4. While gently vortexing, add 25 μ L of the pA-MNase master mix to each sample, including the control samples.

NOTE: The concentration of pA-MNase varies upon preparation, if homemade, and should be therefore tested prior to use upon each independent purification. For pA/G-MNase, 2.5 μ L of the 20x stock should be used.

6.5. Incubate the samples for 30 min at room temperature.

6.6. Place the plate on a 96-well magnetic rack, allow the supernatant to clear for a minimum of 5 min, and then remove and discard the supernatant without disturbing the beads.

6.7. Remove the plate from the magnetic rack and wash the beads with 100 μ L of Wash Buffer, resuspending by gentle pipetting.

7. Directed DNA digestion

7.1. Place the plate on a 96-well magnetic rack, allow the supernatant to clear for a minimum of 5 min, and then remove and discard the supernatant.

7.2. Remove the samples from the magnetic rack and resuspend the beads in 50 μ L of Wash Buffer by gentle pipetting.

7.3. Equilibrate the samples to 0 $^{\circ}$ C in an ice/water mixture for 5 min.

7.4. Remove the samples from the 0 $^{\circ}$ C ice/water bath and add 1 μ L of 100 mM CaCl_2 using a multichannel pipette. Mix well (3–5 times) with gentle pipetting using a larger volume multichannel pipette, and then return the samples to 0 $^{\circ}$ C.

NOTE: Mixing well here is essential. CaCl_2 is added to activate MNase digestion of DNA flanking the protein of interest.

7.5. Start a 10 min timer as soon as the plate is back in the ice/water bath.

7.6. Stop the reaction by pipetting 50 μ L of 2XRSTOP+ Buffer into each well, in the same order as the CaCl_2 was added.

NOTE: Make 2XRSTOP+ Buffer before the 10 min digestion is over to prevent over digestion.

8. Sample fractionation

263
264 8.1. Incubate the samples for 20 min at 37 °C.

265
266 8.2. Spin the plate at 16,000 x *g* for 5 min at 4 °C.

267
268 8.3. Place the plate on a 96-well magnetic rack, allow the supernatant to clear for a minimum of
269 5 min, and transfer supernatants to a fresh 96-well plate. Discard the beads.

270 271 9. DNA extraction

272
273 9.1. Add 1 µL of 10% Sodium Dodecyl Sulfate (SDS) and 0.83 µL of 20 mg/mL Proteinase K to each
274 sample.

275
276 CAUTION: SDS powder is harmful if inhaled. Users should use in well-ventilated spaces wearing
277 goggles, gloves, and an N95-grade respirator, handling with care.

278
279 9.2. Mix the samples by gentle pipetting.

280
281 9.3. Incubate the samples for 10 min at 70 °C.

282
283 9.4. Return the plate to room temperature and add 46.6 µL of 5 M NaCl and 90 µL of 50% PEG
284 4000. Mix by gentle pipetting.

285
286 9.5. Add 33 µL of polystyrene–magnetite beads to each sample and incubate for 10 min at room
287 temperature.

288
289 NOTE: Be sure to bring polystyrene–magnetite beads to room temperature (~30 min) and mix
290 well before using.

291
292 9.6. Place the plate on a magnetic rack and allow the supernatant to clear for ~5 min, and then
293 carefully discard the supernatant without disturbing the beads.

294
295 9.7. Rinse 2x with 150 µL of 80% ethanol without disturbing the beads.

296
297 CAUTION: Ethanol is highly flammable and causes skin, eye, and lung irritation. Perform this step
298 with appropriate laboratory clothing and in a vented hood.

299
300 9.8. Spin the plate briefly at 1000 x *g* for 30 s. Place the plate back on a 96-well magnetic rack
301 and remove all residual EtOH without disturbing the beads.

302
303 9.9. Air-dry the samples for ~2–5 min.

304
305 NOTE: Do not dry the beads for longer than 5 min. If diligent about removing the EtOH, 2–3 min
306 of drying is sufficient.

9.10. Resuspend the beads with 37.5 µL of 10 mM Tris-HCl (pH 8) and incubate for 5 min at room temperature.

9.11. Place the plate on a magnetic rack, and allow the beads to bind for 5 min.

9.12. Transfer 36.5 µL of the supernatant to a fresh thermocycler compatible 96-well plate. Discard the beads.

NOTE: The experiment can be stopped here by storing samples at -20 °C or can continue with the library build (steps 10–15).

10. End repair, phosphorylation, adenylation

NOTE: The reagents are sourced as referenced in the **Table of Materials**. The below protocol follows a similar method to the commercial kit such as NEBNext Ultra DNA II kit.

10.1. Dilute 5 U/µL of T4 DNA polymerase 1:20 in 1x T4 DNA ligase buffer.

10.2. Prepare an end-repair/3'A master mix: 2 µL of 10x T4 DNA ligase buffer, 2.5 µL of 10 mM dNTPs, 1.25 µL of 10 mM ATP, 3.13 µL of 40% PEG 4000, 0.63 µL of 10 U/µL T4 PNK, 0.5 µL of diluted T4 DNA polymerase, 0.5 µL of 5U/µL Taq DNA polymerase, with a total volume of 13.5 µL per reaction.

NOTE: Be sure to bring 40% PEG 4000 to room temperature before pipetting.

10.3. Add 13.5 µL of end-repair/3'A master mix to 36.5 µL of DNA.

10.4. Mix the reaction by quick vortex, and then a quick spin (500 x g for 10 s).

10.5. Incubate using the following reaction conditions in a pre-cooled thermocycler with a heated lid for temperatures >20 °C. Use the reaction conditions: 12 °C for 15 min, 37 °C for 15 min, 72 °C for 20 min, hold at 4 °C.

11. Adapter ligation

NOTE: Keep the samples on ice while setting up the following reaction. Allow ligase buffer to come to room temperature before pipetting. Dilute the Adaptor (see **Table of Materials**) in a solution of 10 mM Tris-HCl containing 10 mM NaCl (pH 7.5). Due to the low yield, do not pre-quantify the CUT&RUN-enriched DNA. Rather, generate 25-fold dilutions of the adaptor, using a final working adaptor concentration of 0.6 µM.

11.1. Make a ligation master mix: 55 µL of ligase buffer (2x), 5 µL of T4 DNA ligase, and 5 µL of diluted Adaptor, with a total volume of 65 µL per reaction.

351
352 11.2. Add 65 μ L of the master ligation mix to 50 μ L of DNA from step 10.5.

353
354 11.3. Mix by quick vortexing, followed by quick spinning (500 x *g* for 10 s).

355
356 11.4. Incubate at 20 °C in a thermocycler (without a heated lid) for 15 min.

357
358 NOTE: Proceed immediately to the following step.

359 360 **12. USER digestion**

361
362 12.1. Add 3 μ L of USER enzyme to each sample, vortex, and spin (500 x *g* for 10 s).

363
364 12.2. Incubate in thermal cycler at 37 °C for 15 min (heated lid set to 50 °C).

365 366 **13. Polystyrene–magnetite bead clean-up following ligation reaction**

367
368 NOTE: Allow polystyrene–magnetite beads to equilibrate at room temperature (~30 min). Vortex
369 to homogenize the bead solution before using. Perform the following steps at room temperature.

370
371 13.1. Add 39 μ L (0.33x) of polystyrene–magnetite bead solution to each well containing adaptor-
372 ligated DNA.

373
374 13.2. Mix thoroughly by pipetting, and then incubate the samples at room temperature for 15
375 min to allow DNA to bind to the beads.

376
377 13.3. Place the samples on a 96-well magnetic rack and incubate for 5 min until the supernatant
378 is clear.

379
380 13.4. Keep the plate on the magnetic rack and carefully remove and discard the supernatant
381 without disturbing the beads.

382
383 13.5. Rinse the beads with 200 μ L of 80% EtOH without disturbing the beads.

384
385 13.6. Incubate for 30 s on a 96-well magnetic rack to allow the solution to clear.

386
387 13.7. Remove and discard the supernatant without disturbing the beads.

388
389 13.8. Repeat steps 13.5–13.7 for a total of two washes.

390
391 13.9. Spin the plate briefly at 500 x *g* for 10 s, place the plate back on a 96-well magnetic rack,
392 and remove residual EtOH without disturbing the beads.

393
394 13.10. Keep the plate on the magnetic rack and air-dry the samples for 2 min.

NOTE: Do not over-dry the beads.

13.11. Remove the plate from the magnetic rack and resuspend the beads in 28.5 μ L of 10 mM Tris-HCl (pH 8).

CAUTION: Hydrochloric acid is very corrosive. Users should handle it with care in a chemical fume hood wearing goggles, gloves, and a lab coat.

13.12. Thoroughly resuspend beads by pipetting, taking care to not produce bubbles.

13.13. Incubate for 5 min at room temperature.

13.14. Place the plate on a 96-well magnetic rack and allow the solution to clear for 5 min.

13.15. Transfer 27.5 μ L of supernatant to a new PCR plate and discard the beads.

14. Library enrichment

NOTE: Primers are diluted with the same solution as the adaptor. For this library build, use a final working primer concentration of 0.6 μ M.

14.1. Add 5 μ L of diluted indexed primer (see **Table of Materials**) to each sample.

NOTE: Each sample needs a different index to be identified during sequencing.

14.2. Prepare a PCR master mix: 10 μ L of 5x high fidelity PCR buffer, 1.5 μ L of 10 mM dNTPs, 5 μ L of diluted Universal primer, 1 μ L of 1 U hot start high fidelity polymerase, with a total master mix volume of 17.5 μ L per sample.

14.3. Add 17.5 μ L pf PCR mix to 32.5 μ L of purified adaptor-ligated DNA (5 μ L of indexed primer is included in this volume).

14.4. Mix the solution by pipetting.

14.5. Incubate in a thermocycler using the following reaction conditions with a maximum ramp rate of 3 $^{\circ}$ C/s: 98 $^{\circ}$ C for 45 s, 98 $^{\circ}$ C for 45 s, 60 $^{\circ}$ C for 10 s, repeat the second and third steps 21 times, 72 $^{\circ}$ C for 1 min, hold at 4 $^{\circ}$ C.

NOTE: The samples can be kept at 4 $^{\circ}$ C for short-term storage or -20 $^{\circ}$ C for long-term storage.

15. Polystyrene–magnetite bead clean-up

15.1. Add 60 μ L (1.2x) of polystyrene–magnetite beads to each sample.

439 15.2. Resuspend the beads by pipetting and incubate for 15 min at room temperature.

441 15.3. Place the plate on a magnetic rack for 5 min until the solution is clear.

443 15.4. Discard the supernatant and rinse the beads with 200 μ L of 80% EtOH without disturbing the beads.

445 15.5. Repeat the wash step for a total of two 80% EtOH washes.

447 15.6. Spin the plate at 500 x *g* for 10 s, place the plate on a 96-well magnetic rack, and allow the beads to bind for 5 min.

449 15.7. Pipette to remove excess EtOH without disturbing the beads and allow the beads to air-dry for 2 min.

451 NOTE: Do not over-dry the beads.

453 15.8. Resuspend the beads in 21 μ L of nuclease-free water and incubate for 5 min at room temperature.

455 15.9. Place the plate on a magnetic rack and allow the solution to clear for 5 min.

457 15.10. Transfer 20 μ L of the supernatant to a new plate.

459 NOTE: The experiment can be stopped here by storing the sample at -20 °C.

461 15.11. Quantify library concentrations with a fluorometer (see **Table of Materials**), using a 1x HS reagent.

463 15.12. If the concentration allows, run 30 ng of sample on 1.5% agarose gel with a low molecular weight ladder to visualize. Alternatively, visualize on a Fragment Analyzer or related instrument.

465 15.13. Sequence libraries on an Illumina platform to obtain ~50,000–100,000 uniquely mapped reads.

467 **REPRESENTATIVE RESULTS:**

469 Here, a detailed protocol is presented for single-cell protein profiling on chromatin using a 96-well manual format uliCUT&RUN. While results will vary based on the protein being profiled (due to protein abundance and antibody quality), cell type, and other contributing factors, anticipated results for this technique are discussed here. Cell quality (cell appearance and percent of viable cells) and single-cell sorting should be assessed prior to or at the time of live-cell sorting into the NE buffer. An example of ES cell colonies and cell sorting is shown in **Figure 2A,B**. Specifically, low-quality cells should not be used, and if the quality is an issue, care should be taken to follow

guidelines for the specific cell type. In addition, accurate cell sorting by the cell sorting instrument should be assessed in advance of experimentation. For example, test cells could be sorted and stained using Hoechst 33342 stain and counted to assure either 0 or 1 cell is found in each well. If single cells are not found, sorting conditions must be optimized. After library preparation, samples can be assessed on either an agarose gel (if the concentration permits for loading of 30 ng or more, as there is a lower limit to DNA visualization on an agarose gel) or a Fragment Analyzer (or similar device such as a TapeStation or Bioanalyzer) prior to sequencing and example results are shown in **Figure 2C,D**. Specifically, the expected size distribution is from ~150 to ~500 bp. In higher cell amounts, CUT&RUN performed on large proteins (such as histones) will have a right-sided size distribution, where the majority of DNA will be seen ~270 bp; however, this shoulder is typically not observed in single-cell experiments.

After sequencing, the quality of the sequencing reads should be assessed using FASTQC. The percent of uniquely mapping reads should be determined. Typically, 0.5%–10% uniquely mapping reads are observed in single-cell experiments. These mapping percentages are similar to other DNA-based single-cell techniques³⁰. Next, the size distribution of the reads after mapping should be determined to assure the profile is similar to pre-sequencing (with the adaptor sequence no longer contributing to the read sizes).

After data quality has been assessed, protein occupancy can be visualized using various methods: single locus genome browser images can be visualized using UCSC genome browser or IGV (**Figure 3A**) and genome-wide occupancy patterns over specific genomic coordinates can be visualized using metaplots (**Figure 3B, bottom**), heatmaps (**Figure 3B, top**), or 1D heatmaps (**Figure 3C**). For more information on data analysis, refer to the study by Patty and Hainer²⁷. Single-cell data from a diploid cell will result in up to four reads contributing to each locus (four reads if the cell was in mitosis), but more often one or two reads. Therefore, the data is binary, and a high background can be more easily mistaken for occupancy, relative to high cell experiments. Therefore, it is recommended to perform a parallel CUT&RUN experiment on a high cell number (5,000 to 100,000 cells), if possible, to acquire all the possible binding locations for the protein of interest. Then, single-cell data can be compared to possible binding locations. In the examples shown in **Figure 3**, single-cell CTCF uliCUT&RUN results are compared to high cell CTCF uliCUT&RUN (**Figure 3A**) or ChIP-seq (**Figure 3B,C**). As demonstrated previously, it is found that CTCF, SOX2, and NANOG single-cell uliCUT&RUN peaks largely represented stronger peaks from high cell ChIP-seq datasets²³.

FIGURE AND TABLE LEGENDS:

Figure 1: Schematic of the uliCUT&RUN protocol. Cells are harvested and sorted into a 96-well plate containing NE buffer. Individual nuclei are then bound to ConA-conjugated paramagnetic microspheres, and sequentially an antibody (targeting the protein of interest) and pA-MNase or pA/G-MNase are added. Protein-adjacent DNA is cleaved *via* MNase, and DNA is then purified for use in library preparation. This figure was created with Biorender.com.

Figure 2: Example results from cell sorting and quality control of uliCUT&RUN libraries. (A) Image of high-quality murine embryonic stem (ES) cells. Scale bar: 200 μ m. **(B)** Output from

single-cell sorting after adding 7AAD to harvested ES cells and sorting on a FACS instrument. (C) Ethidium bromide-stained agarose gel depicting completed uliCUT&RUN libraries. Lane 1 is a low molecular weight ladder and lanes 2–21 are examples of successful individual single-cell uliCUT&RUN libraries prior to sequencing. (D) Ethidium bromide-stained agarose gel depicting sub-optimal and optimal completed uliCUT&RUN libraries. Lane 1 is a low molecular weight ladder, lane 2 is a sub-optimal library due to inefficient MNase digestion, and lane 3 is a successful library with appropriate digestion. (E) Fragment analyzer distribution of one single cell uliCUT&RUN library prior to sequencing.

Figure 3: Example of expected results for single ES cell uliCUT&RUN data. (A) Browser track of high cell number (5,000 cells) CTCF or negative control (No Antibody, No Ab) uliCUT&RUN (top two tracks) and single-cell CTCF uliCUT&RUN. The image is reproduced, with permission, from Patty and Hainer²⁷. (B) Heatmaps (top) and metaplots (bottom) of single-cell CTCF or negative control (No Ab) uliCUT&RUN over previously published CTCF ChIP-seq sites (GSE11724). The image is reproduced, with permission, from Hainer et al.²³. (C) 1D heatmaps of single-cell CTCF or negative control (No Ab) uliCUT&RUN over previously published CTCF ChIP-seq sites (GSE11724). The image is reproduced, with permission, from Hainer et al.²³.

Table 1: Composition of various buffers used in this protocol. Volume of stock solution required is listed with final concentration written in parentheses.

DISCUSSION:

CUT&RUN is an effective protocol to determine protein localization on chromatin. It has many advantages relative to other protocols, including: 1) high signal-to-noise ratio, 2) rapid protocol, and 3) low sequencing read coverage required thus leading to cost savings. The use of Protein A- or Protein A/G-MNase enables CUT&RUN to be applied with any available antibody; therefore, it has the potential to quickly and easily profile many proteins. However, adaptation to single-cell for any protein profiling on chromatin has been difficult, especially when compared to single-cell transcriptomics (i.e., scRNA-seq), due to the low copy number of DNA relative to RNA (two to four copies of DNA versus possible thousands of RNA copies).

In the protocol detailed above, several critical steps should be considered. First, the appropriate sorting of cells is dependent on the cell (or tissue) type, and care should be taken for accurate sorting. It is recommended to test how effective single-cell sorting is with the instrument in advance of any experiment. Second, effective antibody choice is essential. Before proceeding to a single-cell application, it is recommended to test the antibody in a high cell number experiment (as well as other standard antibody tests, such as confirming specificity using western blot after knockdown, titration of the antibody in CUT&RUN experiments, etc.). Third, use a negative control, such as IgG or no primary antibody, because an appropriate comparison to the experimental samples is essential for the interpretation of the data quality and biological results. When comparing single-cell experimental results to a high cell number dataset, the negative control single-cell experiments should have less read coverage over those binding sites identified in the high cell experiment and rather have a random distribution of reads across the genome (with a bias for open regions of chromatin). Fourth, care should be taken when adding and

activating the Protein A- or Protein A/G-MNase so as not to over digest the chromatin: do not overheat the samples with your hands, maintain the samples in an ice/water-bath temperature (0 °C), and chelate the reaction at the appropriate time. Fifth, care should be taken throughout the uliCUT&RUN experiment and library preparation, due to low material. For example, extended incubation on the magnetic rack during bead binding to assure the supernatant has cleared and taking care not to disturb the beads when removing the supernatant are essential for sufficient yield. Sixth, depending on the questions being addressed, the number of single-cell experiments being performed is an important consideration. Some of the single-cell experiments will fail (as with all low-input experiments), and, therefore, the number of positive experimental results required for appropriate interpretation should be considered in advance of beginning the experiment. The number of cells to include in the experiment is dependent on the amount of experimental data required by the investigator and the quality of the antibody. Finally, note that equivalent results could be achieved with reduced volumes of many aspects of this protocol. Steps, where the volume was reduced by 50%, include the volume of NE buffer, wash buffer, primary antibody mixture (including the amount of primary antibody), pA-MNase mixture (including the amount of pA-MNase), and all steps in the library preparation.

Based on the complicated nature of factor profiling on chromatin, there are many potential sources of issues and places where troubleshooting may become necessary. While there may be many steps where issues can arise, three major issues have been observed here: 1) low DNA yield for input into library build; 2) high background signal in experimental samples, and 3) low yield after library build. If there is insufficient DNA for library preparation and sequencing (point 1), note the following troubleshooting advice: a) there may have been incomplete membrane lysis and therefore the lysis time with NE buffer can be increased; b) there may have been inefficient binding of the nucleus to the ConA-conjugated paramagnetic microspheres and this could be remedied through appropriate mixing upon addition of these beads; c) there may have been too little antibody added, and therefore it is recommended to perform a titration of antibody to identify the most effective amount; d) incubation times with either the primary antibody or the Protein A- or Protein A/G-MNase are either too short (i.e., not enough time to permit binding) or too long (these are native, uncrosslinked samples), and could be optimized; e) the interaction of the target protein with chromatin could be too transient to capture in native conditions and therefore crosslinking CUT&RUN could be performed²⁸. While single-cell datasets will yield high background, there may be excessively high background where the signal is hard to interpret from the background (point 2). For this issue, note the following advice: a) the blocking step with EDTA to prevent pre-emptive MNase digestion could be increased or optimized; b) if there is excessive cutting, it could be due to having too much Protein A- or Protein A/G-MNase, and therefore a titration of appropriate amounts can be performed; c) over digestion by MNase could result in the high background, and therefore the appropriate mixing of calcium chloride upon addition and optimization for MNase digestion time should be assessed. Finally, efficient uliCUT&RUN-enriched DNA may have been recovered, but a low amount of library may be recovered (point 3). For this issue, the following are recommended: a) appropriate handling and use of polystyrene-magnetite beads to assure the correct purification and no DNA loss; specifically, it is recommended to have 15 min incubations and a minimum of 5 min to magnetize beads to prevent loss; b) under-amplification of the library at the PCR stage would result in low yield and

therefore the appropriate cycles should be determined using qPCR (as previously established for ATAC-seq libraries²⁹).

As with all technologies, there are limitations to uliCUT&RUN that should be considered before initiating any experimentation. First, these experiments are designed and optimized for native conditions, and therefore if a protein is only transiently interacting with chromatin, a crosslinking approach may be necessary to ensure recovery of the interaction. Second, as with all antibody-based techniques, the quality of the antibody is important. Care should be taken to assure the quality and consistency of the antibody in advance of undertaking any experiments. Third, MNase background cutting can occur and, while there is a consistently lower background signal in CUT&RUN relative to other experiments, the background signal can be high in single-cell experiments and therefore appropriate controls and analyses should be performed. While the binary nature of single-cell profiling data limits the visualization, more advanced computational genomic technologies, such as dimensional reduction and others can be performed (as previously described²⁷). Finally, while single-cell profiling has been expanded here to 96-well format, this is low throughput relative to other single-cell technologies that utilize 10xGenomics or other formats.

Tethering-based profiling technologies such as ChEC-seq²⁰, CUT&Tag²⁴, CUT&RUN²¹, and uliCUT&RUN²³, can determine factor localization on chromatin with a faster experimental timeline, lower background, and lower cost than traditional profiling technologies, such as ChIP-seq. Therefore, these are very exciting technologies for application to precious samples such as patient samples or early developmental samples. Furthermore, application to single cells can provide complementary studies performed using other single-cell experiments such as scRNA-seq and scATAC-seq³⁰. As described using these more broadly used single-cell technologies, novel insights can be gained relative to bulk cell experiments. Single-cell protein profiling on chromatin is anticipated to become more regularly used as the technologies continue to improve and permit more parallelization.

ACKNOWLEDGEMENTS:

We thank members of the Hainer Lab for reading and comments on an earlier version of this manuscript. This project used the NextSeq500 available at the University of Pittsburgh Health Sciences Sequencing Core at UPMC Children's Hospital of Pittsburgh for sequencing with special thanks to its director, William MacDonald. This research was supported in part by the University of Pittsburgh Center for Research Computing through the computer resources provided. This work was supported by the National Institutes of Health Grant Number R35GM133732 (to S.J.H.).

DISCLOSURES:


The authors declare no competing interests related to this project.


REFERENCES:

1. Gilmour, D. S., Lis, J. T. In vivo interactions of RNA polymerase II with genes of *Drosophila melanogaster*. *Molecular and Cellular Biology*. **5** (8), 2009–2018 (1985).

2. Solomon, M. J., Varshavsky, A. Formaldehyde-mediated DNA-protein crosslinking: a probe for in vivo chromatin structures. *Proceedings of the National Academy of Sciences of the United States of America*. **82** (19), 6470–6474 (1985).
3. Irvine, R. A., Lin, I. G., Hsieh, C.-L. DNA methylation has a local effect on transcription and histone acetylation. *Molecular and Cellular Biology*. **22** (19), 6689–6696 (2002).
4. Albert, I. et al. Translational and rotational settings of H2A.Z nucleosomes across the *Saccharomyces cerevisiae* genome. *Nature*. **446** (7135), 572–576 (2007).
5. Blat, Y., Kleckner, N. Cohesins bind to preferential sites along yeast chromosome III, with differential regulation along arms versus the centric region. *Cell*. **98** (2), 249–259 (1999).
6. Ren, B. et al. Genome-wide location and function of DNA binding proteins. *Science*. **290** (5500), 2306–2309 (2000).
7. Rhee, H. S., Pugh, B. F. Comprehensive genome-wide protein-DNA interactions detected at single-nucleotide resolution. *Cell*. **147** (6), 1408–1419 (2011).
8. He, Q., Johnston, J., Zeitlinger, J. ChIP-nexus enables improved detection of in vivo transcription factor binding footprints. *Nature Biotechnology*. **33** (4), 395–401 (2015).
9. O'Neill, L. P., Turner, B. M. Immunoprecipitation of native chromatin: NChIP. *Methods*. **31** (1), 76–82 (2003).
10. Schmidl, C., Rendeiro, A. F., Sheffield, N. C., Bock, C. ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors. *Nature Methods*. **12** (10), 963–965 (2015).
11. Cao, Z., Chen, C., He, B., Tan, K., Lu, C. A microfluidic device for epigenomic profiling using 100 cells. *Nature Methods*. **12** (10), 959–962 (2015).
12. Shankaranarayanan, P. et al. Single-tube linear DNA amplification (LinDA) for robust ChIP-seq. *Nature Methods*. **8** (7), 565–567 (2011).
13. Rotem, A. et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. *Nature Biotechnology*. **33** (11), 1165–1172 (2015).
14. Grosselin, K. et al. High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. *Nature Genetics*. **51** (6), 1060–1066 (2019).
15. Adli, M., Bernstein, B. E. Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq. *Nature Protocols*. **6** (10), 1656–1668 (2011).
16. Zwart, W. et al. A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. *BMC Genomics*. **14**, 232 (2013).
17. Valensisi, C., Liao, J. L., Andrus, C., Battle, S. L., Hawkins, R. D. cChIP-seq: a robust small-scale method for investigation of histone modifications. *BMC Genomics*. **16**, 1083 (2015).
18. Brind'Amour, J. et al. An ultra-low-input native ChIP-seq protocol for genome-wide profiling of rare cell populations. *Nature Communications*. **6**, 6033 (2015).
19. Schmid, M., Durussel, T., Laemmli, U. K. ChIC and ChEC; genomic mapping of chromatin proteins. *Molecular Cell*. **16** (1), 147–157 (2004).
20. Zentner, G. E., Kasinathan, S., Xin, B., Rohs, R., Henikoff, S. ChEC-seq kinetics discriminates transcription factor binding sites by DNA sequence and shape in vivo. *Nature Communications*. **6**, 8733 (2015).
21. Skene, P. J., Henikoff, S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. *eLife*. **6**, e21856 (2017).
22. Meers, M. P., Bryson, T. D., Henikoff, J. G., Henikoff, S. Improved CUT&RUN chromatin profiling tools. *eLife*. **8**, e46314 (2019).

23. Hainer, S. J., Bošković, A., McCannell, K. N., Rando, O. J., Fazio, T. G. Profiling of pluripotency factors in single cells and early embryos. *Cell*. **177** (5), 1319–1329.e11 (2019).
24. Kaya-Okur, H. S. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. *Nature Communications*. **10** (1), 1930 (2019).
25. Carter, B. et al. Mapping histone modifications in low cell number and single cells using antibody-guided chromatin tagmentation (ACT-seq). *Nature Communications*. **10** (1), 3747 (2019).
26. Gopalan, S., Wang, Y., Harper, N. W., Garber, M., Fazio, T. G. Simultaneous profiling of multiple chromatin proteins in the same cells. *Molecular Cell*. **81** (22), 4736–4746.e5 (2021).
27. Patty, B. J., Hainer, S. J. Transcription factor chromatin profiling genome-wide using uliCUT&RUN in single cells and individual blastocysts. *Nature Protocols*. **16** (5), 2633–2666 (2021).
28. Zheng, X.-Y., Gehring, M. Low-input chromatin profiling in Arabidopsis endosperm using CUT&RUN. *Plant Reproduction*. **32** (1), 63–75 (2019).
29. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nature Methods*. **10** (12), 1213–1218 (2013).
30. Buenrostro, J. D. et al. Single-cell chromatin accessibility reveals principles of regulatory variation. *Nature*. **523** (7561), 486–490 (2015).






E



Size (bp)



Volume of buffers needed is dependent on number of s
All buffers can be stored at 4 °C for up to one year, unle

Nuclear Extraction Buffer (NE; 50 mL):

Binding Buffer (20 mL):

Wash Buffer (100 mL):

Blocking Buffer (5 mL):

2XRSTOP+ Buffer (15 mL):

PBS + 1% FBS (5 mL):

amples.

ss otherwise noted.

1 mL of 1M HEPES-KOH pH 7.9 (20 mM)

500 μ L of 1 M KCl (10 mM)

12.5 μ L of 2 M Spermidine (0.5 mM)

500 μ L of 10% Triton X-100 (0.1%)

12.5 mL of 80% Glycerol (20%)

Volume up to 50 mL with autoclaved double distilled water

Store at 4 °C up to 1 year

Add protease inhibitors fresh upon each use of buffer

Caution: KOH and Triton X-100 are both hazardous. Use in a chemical fume hood wearing gloves, goggles

400 μ L of 1 M HEPES-KOH pH 7.9 (20 mM)

200 μ L of 1 M KCl (10 mM)

20 μ L of 1 M CaCl_2 (1 mM)

20 μ L of 1 M MnCl_2 (1 mM)

Volume up to 20 mL with autoclaved double distilled water

Store at 4 °C up to 1 year

2 mL of 1 M HEPES-KOH pH 7.5 (20 mM)

3 mL of 5 M NaCl (150 mM)

25 μ L of 2 M Spermidine (0.5 mM)

333 μ L of 30% BSA (0.1%)

Volume up to 100 mL with autoclaved double distilled water

Store at 4 °C up to 1 year

Add protease inhibitors fresh upon each use of buffer

Made on the same day experiment is being performed

5 mL of pre-made Wash Buffer with protease inhibitors included

20 μ L of 0.5M EDTA (2 mM)

600 μ L of 5 M NaCl (200 mM)

600 μ L of 0.5 M EDTA (20 mM)

300 μ L of 0.2 M EGTA (4 mM)

Volume up to 15 mL with autoclaved double distilled water

Store at 4 °C up to 1 year

Add fresh per 1 mL of STOP buffer:

5 μ L of 10 mg/mL RNase A (50 μ g/mL)

2 μ L of 20 mg/mL Glycogen (40 μ g/mL)

1 μ L of 10 ng/mL heterologous spike-in DNA (10 pg/mL)

5 mL of PBS

1% FBS

Mix well and filter sterilize

Store at 4 °C up to 1 month

and a lab coat for safety.



We thank the Reviewers for their comments. Our responses are in Red.

Reviewer #1:**Major Concerns:**

The authors should specify the improvement of this protocol to the one they published on Benjamin J. Patty & Sarah J. Hainer et al. Nature protocols and Sarah J. Hainer, Thomas G. Fazio et al. Current protocols. Otherwise, I don't see the point to publish the same thing again and again.

We appreciate the Reviewers comment. When invited to write this article, we noted to the editors that we had previously published those above-mentioned articles. The editors still wanted us to contribute and noted that JOVE finds novelty in the accompanying video that is generated. Therefore, we obliged and put together this manuscript. Of note, we have updated our protocol to include 96-well format for single cell application, which is uniquely discussed in this protocol.

Reviewer #2:**Manuscript Summary:**

Lardo and Hainer., "Single cell factor localization on chromatin using uliCUT&RUN"

In this manuscript, Lardo and Hainer detail their protocol for single cell CUT&RUN assays in a plate (96well) format. CUT&RUN and other similar methods have become the predominant method for characterizing protein-DNA interactions in the context of the nucleus and methods that can provide single cell resolution are increasingly important. Critically, single cell experiments typically require high numbers of cells so optimized methods for high-throughput work are valuable.

The methods paper clearly describes most of the steps in the protocols used by the laboratory. However, the rationale and requirements for many critical steps could use additional detail or discussion, particularly to highlight potential pitfalls. Including critical lessons learned as part of establishing these methods would facilitate other researchers in make modifications, such as automation, that would further take advantage of the laboratory's work. A subset of these are highlighted below but the authors should review their manuscript for additional locations where specific reagent choices were critical for the success of their method.

Thank you for these suggestions. We have gone through all your suggestions and added discussion of these items as well as a few other aspects that, upon re-reading, we identified as requiring more discussion.

Major Concerns:

The selection of the cell sorter (and it's set up) is likely valuable. Many of the details of the protocol cited here likely directly tied to the instrumentation and its limitations. These would include the number of cells to start with (2.7), target volume of lysis buffer (3.1), etc. Is 100uL used because that is the lowest volume that would successfully give high fractions of cells loaded into the well? What is the fraction of wells with cells you expect?

Thank you for this discussion. The instrument and cell input go hand in hand. We have used FACS Aria II instruments (included in our Materials Table), and the recommended input is 1 million cells (in 1mL), which is why that is described here. We recovered 80-95% of wells with single cells, and the remainder with 0 cells. We have now recommended that readers test the sorting efficiency in advance (Lines 157-158; 380-381; 454-456). We have always

initially lysed the cells in 100 μ L; partly to make sure it is a high volume and we can capture the cell, and also out of habit. This is not a volume we have altered in our protocol to this point.

Along the same lines, the choice of plate you are using is likely critical as well - presumably favoring low bind v-bottom plates? More explicit inclusion of details where an uninformed user could scuttle their experiment would be beneficial throughout the manuscript.

Thank you for this recommendation, we have included the plates in the materials table.

With the cell spin down (3.5) how much loss is expected? Are there cell types tested where the nucleus is not reliably brought to the bottom of the well.

With this low-speed spin, we do not observe lysis of murine ES cells. We have performed CUT&RUN on a few other cell types, and in bulk cells, we do not observe lysis; however we have not performed single cell CUT&RUN in other cell types.

In all cases, the volumes of reagents used are enormous given the very tiny amount of sample. Why were such large volumes chosen? Have the authors explored the impact of lowering these volumes? Many reactions would be expected to work better in a lower volume situation, but what is the impact on the MNase reaction? Is that less well controlled? A further discussion on these points would be helpful.

Thank you for pointing this out. We have been testing reductions in some of the reagents recently in our lab and have obtained robust results for some but not all reagents. We are including here what we are 100% confident in working; but have now added a discussion about how some of these volumes could be decreased based on your suggestion (Lines 481-485).

For the adaptor ligation/library construction, how different is this method from kitted protocols such as NEB Ultrall where miniaturization of the reactions has been demonstrated with robust results?

The library construction method we use follows a similar protocol to the Illumina kit, but by sourcing the reagents separately we can save money. However, we have also tested using the kit for library preparation and it works as well.

In analysis, if only 0.5%-10% of the reads are alignable, what are the other 90+% of the reads? Are they all just the spike in? If so, to get 100k aligned reads, you are needing 1m-20m reads per cell?

Yes, as is common in all single cell DNA-based datasets (including scATAC-seq and scDNase-seq), there are small % mapped reads in these datasets (we have noted this on Line 394). The majority of the reads are spike in and random bacterial reads. In our original 2019 paper (Hainer et al Cell 2019) where we originally described this method, we compare CUT&RUN data to scATAC-seq data and actually find a higher percent mapping. And yes, you are correct that given the low mapping, the amount of raw sequencing reads required is high.

The negative control in all ChIP experiments is always challenging to interpret since so few molecules would be expected to be released. What results are you observing in failed experiments where the negative control is proving valuable as a control for the experiment? What peaks or data points are you able to exclude?

In single cell experiments, the negative control is also hard to interpret. However, if one has high cell CUT&RUN (or ChIP-seq) data to compare the single cell datasets to (as we suggest in this article), the negative control would have less reads contributing to the locations that high cell datasets have identified as a binding site for the protein of interest, but rather have a random distribution of reads across the majority of the genome (with a bias for open regions of chromatin). In single cell experiments, the negative control can be used as an “input” type, where reads could be subtracted. However, given the sparse nature of single cell datasets, we do not recommend this, but rather use the negative control as a comparison of reads over the locations of interest (as defined by high cell datasets). (Lines 460-466)

The authors indicate that, because of the expected failure rate, additional samples should be done (line 460). How do you decide on the number of cells you want to process to compensate for an expected failure rate?

This is complicated, as it is largely dependent on the factor being profiled. For robust antibodies, the number of cells is likely lower than for a weak antibody. In addition, it is possibly cell type dependent. (Lines 476-480)

The authors indicate a number of possible failure modes but were these observed or simply hypothetical? For example, incomplete lysis of a single cell would seem to be quite unlikely. These are observed failures in CUT&RUN experiments we have performed, although this includes both high cell and single cell experiments. We wanted to be thorough in what we included, and therefore included everything we have experienced.

Minor Concerns:

Typo in line 110: presumably this should be pg/uL?

It is actually pg/mL, however, thank you for identifying that we did not detail carefully enough the volume added here (15 μ L).

For 96 well work, the choice of the magnetic rack can be a critical step and should be included.

Thank you for this suggestion! We have included the magnetic rack we prefer to use in the Materials Table.

The baseline for the trace in figure 2D is clearly set up incorrectly.

Thank you for this comment. This is an example of a library pre-sequencing, and therefore adapters are still present, so the size distribution is ~200-400bp. This trace is reflective of a typical distribution before adapters are removed for the analysis.

Reviewer #3:

Manuscript Summary:

It is a well-written manuscript although the method has been described and published on Cell (2019) and Nature Protocols (2021). A few questions/ comments are listed as minor concerns.

Minor Concerns:

Line 117: Please briefly describe Bio-Mag ConA beads.

Thank you for this comment; we have included a “NOTE” describing these beads (Line 119-120)

Line 145: Please briefly describe the purpose of adding 7-AAD.

Thank you for this comment; we have included a “NOTE” describing the purpose of 7-AAD (Line 149-150).

Line 216: Please briefly describe the purpose of adding CaCl₂.

Thank you for this comment; we have included a “NOTE” regarding the purpose of CaCl₂ (Line 225-226).

Figure 2C: The DNA visualization on agarose gel is not clear enough.

Thank you for this comment; the gel is hard to see. We have provided a higher quality image for the reads to visualize more easily (Figure 2C)

Figure 3: The figure has been published in Reference 23. Authors may consider using another set of uliCUT&RUN data as example, either on different cell or using different antibody to convince readers this protocol's reliability and wide application.

Thank you for the comment; JOVE allows previously published work to be included and since we do not want to “scoop” our own work and publish work for a primary dataset, we have chosen to use previously published datasets.

Line197: add the example of optimal MNase digestion vs. sub-optimal MNase digestion will be beneficial for the readers.

Thank you for the suggestion, we have included this example as Figure 2D.

Line233: It should be 20 mg/mL instead of 20 mg/mm

Thank you for catching this typo. It has been corrected.

ELSEVIER LICENSE TERMS AND CONDITIONS

Nov 03, 2021

This Agreement between Sarah Hainer ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number 5181640468051

License date Nov 03, 2021

Licensed Content Publisher Elsevier

Licensed Content Publication Cell

Licensed Content Title Profiling of Pluripotency Factors in Single Cells and Early Embryos

Licensed Content Author Sarah J. Hainer, Ana Bošković, Kurtis N. McCannell, Oliver J. Rando, Thomas G. Fazzio

Licensed Content Date May 16, 2019

Licensed Content Volume 177

Licensed Content Issue 5

Licensed Content Pages 22

Start Page 1319

End Page 1329.e11

Type of Use	reuse in a journal/magazine
Requestor type	academic/educational institute
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	1
Format	electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Title of new article	Single cell factor localization on chromatin using uliCUT&RUN
Lead author	Sarah Hainer
Title of targeted journal	JOVE
Publisher	MyJove Corp.
Expected publication date	Mar 2022
Portions	Figure 4A, Figure 4B
Requestor Location	Sarah Hainer 4249 Fifth Ave 527 Langley Hall PITTSBURGH, PA 15260 United States Attn: University of Pittsburgh
Publisher Tax ID	98-0397604

Total 0.00 USD

Terms and Conditions

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier's permissions helpdesk [here](#)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be

deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at

<http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. For journal authors: the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use
 - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
 - via non-commercial hosting platforms such as their institutional repository
 - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting.policy](#) for further information.

18. For book authors the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third

party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.10

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
